126 related articles for article (PubMed ID: 8054451)
1. Heparin cofactor II in diabetic patients.
Duboscq C; Quintana I; Barros J; Kordich L
Blood Coagul Fibrinolysis; 1994 Apr; 5(2):201-4. PubMed ID: 8054451
[TBL] [Abstract][Full Text] [Related]
2. Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.
Hara T; Uemoto R; Sekine A; Mitsui Y; Masuda S; Kurahashi K; Yoshida S; Otoda T; Yuasa T; Kuroda A; Ikeda Y; Endo I; Honda S; Yoshimoto K; Kondo A; Tamaki T; Matsumoto T; Matsuhisa M; Abe M; Aihara KI
J Diabetes Investig; 2021 Dec; 12(12):2172-2182. PubMed ID: 34043882
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a reduced heparin cofactor II biological activity in diabetes.
Ceriello A; Quatraro A; Dello Russo P; Marchi E; Milani MR; Giugliano D
Haemostasis; 1990; 20(6):357-61. PubMed ID: 2099324
[TBL] [Abstract][Full Text] [Related]
4. [Heparin cofactor II (HCII) activity and antigen assay and their significance in thrombotic diseases].
Dai CW; Zhang GS
Zhonghua Xue Ye Xue Za Zhi; 2003 Sep; 24(9):452-4. PubMed ID: 14575585
[TBL] [Abstract][Full Text] [Related]
5. An enzyme-linked immunosorbent assay for heparin cofactor II (HCII). Application to the measurement of HCII in clinical materials.
Toulon P; Costa JM; Amiral J
Clin Chim Acta; 1992 Jan; 205(1-2):65-73. PubMed ID: 1521342
[TBL] [Abstract][Full Text] [Related]
6. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
[TBL] [Abstract][Full Text] [Related]
7. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome.
Toulon P; Gandrille S; Remy P; Chadeuf G; Jouvin MH; Aiach M
Nephron; 1992; 60(2):176-80. PubMed ID: 1553002
[TBL] [Abstract][Full Text] [Related]
8. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals.
Aihara K; Azuma H; Takamori N; Kanagawa Y; Akaike M; Fujimura M; Yoshida T; Hashizume S; Kato M; Yamaguchi H; Kato S; Ikeda Y; Arase T; Kondo A; Matsumoto T
Circulation; 2004 Jun; 109(22):2761-5. PubMed ID: 15148272
[TBL] [Abstract][Full Text] [Related]
9. Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II.
Porter JB; Young L; Mackie IJ; Marshall L; Machin SJ
Br J Haematol; 1993 Mar; 83(3):459-65. PubMed ID: 8485052
[TBL] [Abstract][Full Text] [Related]
10. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ
Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786
[TBL] [Abstract][Full Text] [Related]
11. [Dynamic changes and localization of plasma heparin cofactor II before and after delivery in hypertensive pregnancy].
Chen X; Zhang G; Wang C
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):468-70. PubMed ID: 11721410
[TBL] [Abstract][Full Text] [Related]
12. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
13. Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors.
Aihara K; Azuma H; Akaike M; Kurobe H; Takamori N; Ikeda Y; Sumitomo Y; Yoshida S; Yagi S; Iwase T; Ishikawa K; Sata M; Kitagawa T; Matsumoto T
J Atheroscler Thromb; 2009 Apr; 16(2):127-34. PubMed ID: 19403987
[TBL] [Abstract][Full Text] [Related]
14. [Heparin cofactor II (HCII)].
Yoshikawa T; Hayashi T; Suzuki K
Nihon Rinsho; 2004 Dec; 62 Suppl 12():667-70. PubMed ID: 15658419
[No Abstract] [Full Text] [Related]
15. Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion.
O'Driscoll A; Mackie IJ; Porter JB; Machin SJ
Br J Haematol; 1995 May; 90(1):65-70. PubMed ID: 7786797
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji).
Kondo S; Tokunaga F; Kario K; Matsuo T; Koide T
Blood; 1996 Feb; 87(3):1006-12. PubMed ID: 8562924
[TBL] [Abstract][Full Text] [Related]
17. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.
Takamori N; Azuma H; Kato M; Hashizume S; Aihara K; Akaike M; Tamura K; Matsumoto T
Circulation; 2004 Feb; 109(4):481-6. PubMed ID: 14744972
[TBL] [Abstract][Full Text] [Related]
18. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting.
Schillinger M; Exner M; Sabeti S; Mlekusch W; Amighi J; Handler S; Quehenberger P; Kalifeh N; Wagner O; Minar E
Thromb Haemost; 2004 Nov; 92(5):1108-13. PubMed ID: 15543340
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of heparin cofactor II (HCII) and thrombin-HCII complex in patients with disseminated intravascular coagulation.
Noda A; Wada H; Kusiya F; Sakakura M; Onishi K; Nakatani K; Gabazza EC; Asahara N; Tsukada M; Nobori T; Shiku H
Clin Appl Thromb Hemost; 2002 Jul; 8(3):265-71. PubMed ID: 12361205
[TBL] [Abstract][Full Text] [Related]
20. Increased heparin cofactor II levels in women taking oral contraceptives.
Toulon P; Bardin JM; Blumenfeld N
Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
